reverses diabetes type 2

🔥+ reverses diabetes type 2 02 Jun 2020 I wasn't overweight either—a more common aspect of type 2 diabetes,” Cherise says. Cherise was referred to an endocrinologist who ordered additional blood ...

reverses diabetes type 2 Complications. Diabetes increases your risk for many serious health problems. The good news? With the correct treatment and recommended lifestyle changes, ...

sudden weight loss and diabetes
News & Perspective
Drugs & Diseases
CME & Education
Academy
Video
Edition: reverses diabetes type 2 natural treatment cure (🔴 exhaustion) | reverses diabetes type 2 ribbonhow to reverses diabetes type 2 for ENGLISH
Log In
Sign Up It''overview''clinical''workup''treatment''medication''s diabetes and about the care the patient is currently receiving for the disease. The duration of diabetes is significant because the chronic complications of diabetes are related to the length of time the patient has had the disease.

A focused diabetes history should also include the following questions:

  • Is the patient''s hemoglobin A1c (HbA1c; an indicator of long-term glucose control) last measured, and what was it

  • What is the patient’s immunization history - Eg, influenza, pneumococcal, hepatitis B, tetanus, herpes zoster

As circumstances dictate, additional questions may be warranted, as follows:

  • Does the patient give a history of recent polyuria, polydipsia, nocturia, or weight loss - These are symptoms of hyperglycemia

  • Has the patient had episodes of unexplained hypoglycemia - If so, when, how often, and how does the patient treat these episodes

  • Does the patient have hypoglycemia unawareness (ie, does the patient lack the adrenergic warning signs of hypoglycemia) - Hypoglycemia unawareness indicates an increased risk of subsequent episodes of hypoglycemia

  • reverses diabetes type 2 eating (⭐️ junk food) | reverses diabetes type 2 therapyhow to reverses diabetes type 2 for Regarding retinopathy, when was the patient''s most recent lipid levels; is the patient taking lipid-lowering medication

  • Does the patient have a history of neuropathy or are symptoms of peripheral neuropathy or autonomic neuropathy present (including impotence if the patient is male)

  • Does the patient have a history of foot ulcers or amputations; are any foot ulcers present

  • Are frequent infections a problem; at what site

reverses diabetes type 2 blood pressure (👍 natural treatment cure) | reverses diabetes type 2 insulinhow to reverses diabetes type 2 for Dawn phenomenon

The Dawn phenomenon, defined as a blood glucose increase of over 20 mg/dL occurring at the end of the night, appears to be common in type 2 diabetes. In a study of 248 noninsulin-treated patients with type 2 diabetes who underwent continuous glucose monitoring for 2 consecutive days, approximately half were found to have the dawn phenomenon. [107, 108] Patients with the dawn phenomenon had HbA1c levels and 24-hour mean glucose values that were significantly higher than in other patients, the mean differences being 4.3 mmol/mol for HbA1c (0.39%) and 12.4 mg/dL for average 24-hour glucose concentrations. Mean 24-hour glucose did not significantly differ between patients treated with diet alone and those treated with oral antihyperglycemic agents (ie, oral antidiabetic drugs did not eliminate the dawn phenomenon). [107, 108]

Next:

Physical Examination

Early in the course of diabetes mellitus, the physical examination findings are likely to the 1 last update 02 Jun 2020 be unrevealing. Ultimately, however, end-organ damage may be observed. Potential findings are listed in the image below.Early in the course of diabetes mellitus, the physical examination findings are likely to be unrevealing. Ultimately, however, end-organ damage may be observed. Potential findings are listed in the image below.

Possible physical examination findings in patients with type 2 diabetes mellitus.

A diabetes-focused examination includes vital signs, funduscopic examination, limited vascular and neurologic examinations, and a foot assessment. Other organ systems should be examined as indicated by the patient'' pupils are not dilated.

Whether patients develop diabetic retinopathy depends on the duration of their diabetes and on the level of glycemic control maintained. [109, 110] Because the diagnosis of type 2 diabetes often is delayed, 20% of these patients have some degree of retinopathy at diagnosis. The following are the 5 stages in the progression of diabetic retinopathy:

  • Dilation of the retinal venules and formation of retinal capillary the 1 last update 02 Jun 2020 microaneurysmsDilation of the retinal venules and formation of retinal capillary microaneurysms

  • Increased vascular permeability

  • Vascular occlusion and retinal ischemia

  • reverses diabetes type 2 young age (⭐️ natural cure) | reverses diabetes type 2 in young childrenhow to reverses diabetes type 2 for Proliferation of new blood vessels on the surface of the retina

  • Hemorrhage and contraction of the fibrovascular proliferation and the vitreous

The first 2 stages of diabetic retinopathy are known as background or nonproliferative retinopathy. Initially, the retinal venules dilate, then microaneurysms (tiny red dots on the retina that cause no visual impairment) appear. As the microaneurysms or retinal capillaries become more permeable, hard exudates appear, reflecting the leakage of plasma.

Larger retinal arteriolar and venular calibres have been associated with lower scores on memory tests but not with lower scores on other cognitive tests. [111] This association was strong in men. Impaired arteriolar autoregulation may be an underlying mechanism of memory decrements.

Rupture of intraretinal capillaries results in hemorrhage. If a superficial capillary ruptures, a flame-shaped hemorrhage appears. Hard exudates are often found in partial or complete rings (circinate pattern), which usually include multiple microaneurysms. These rings usually mark an area of edematous retina. The patient may not notice a change in visual acuity unless the center of the macula is involved.

Macular edema can cause visual loss; therefore, all patients with suspected macular edema must be referred to an ophthalmologist for evaluation and possible laser therapy. Laser therapy is effective in decreasing macular edema and preserving vision but is less effective in restoring lost vision. (For more information, see Macular Edema in Diabetes.)

Preproliferative and proliferative diabetic retinopathy are the next stages in the progression of the disease. Cotton-wool spots can be seen in preproliferative retinopathy. These represent retinal microinfarcts caused by capillary occlusion; they appear as patches that range from off-white to gray, and they have poorly defined margins.

Proliferative retinopathy is characterized by neovascularization, or the development of networks of fragile new vessels that often are seen on the optic disc or along the main vascular arcades. The vessels undergo cycles of proliferation and regression. During proliferation, fibrous adhesions develop between the vessels and the vitreous. Subsequent contraction of the adhesions can result in traction on the retina and retinal detachment. Contraction also tears the new vessels, which hemorrhage into the vitreous.

Patients with preproliferative or proliferative retinopathy must immediately be referred for ophthalmologic evaluation because laser therapy is effective in this condition, especially before actual hemorrhage occurs.

Often, the first hemorrhage is small and is noted by the patient as a fleeting, dark area, or "" in the field of vision. Because subsequent hemorrhages can be larger and more serious, the patient should be referred immediately to an ophthalmologist for possible laser therapy. Patients with retinal hemorrhage should be advised to limit their activity and keep their head upright (even while sleeping), so that the blood settles to the inferior portion of the retina, thus obscuring less central vision.

Patients with active proliferative diabetic retinopathy are at increased risk of retinal hemorrhage if they receive thrombolytic therapy; therefore, this condition is a relative contraindication to the use of thrombolytic agents.

reverses diabetes type 2 cause hypertension (⭐️ blood sugar range chart) | reverses diabetes type 2 characteristicshow to reverses diabetes type 2 for One study has shown that individuals with gingival hemorrhaging have a high prevalence of retinal hemorrhage. [112] Much of this association is driven by hyperglycemia, making it possible to use gingival tissue to study the natural course of microvascular disease in patients with diabetes.

Foot examination

The dorsalis pedis and posterior tibialis pulses for 1 last update 02 Jun 2020 should be palpated and their presence or absence noted. This is particularly important in patients who have foot infections, because poor lower-extremity blood flow can slow healing and increase the risk of amputation.The dorsalis pedis and posterior tibialis pulses should be palpated and their presence or absence noted. This is particularly important in patients who have foot infections, because poor lower-extremity blood flow can slow healing and increase the risk of amputation.

Documenting lower-extremity sensory neuropathy is useful in patients who present with foot ulcers because decreased sensation limits the patient''Agostino R Jr, Mykkanen L, Tracy R, Howard B, Rewers M, et al. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care. 1999 Apr. 22(4):562-8. [Medline].

  • Busko M. Gray-matter atrophy may drive cognitive decline in diabetes. Medscape Medical News. August 22, 2013. [Full Text].

  • Moran C, Phan TG, Chen J, et al. Brain atrophy in type 2 diabetes: regional distribution and influence on cognition. Diabetes Care. 2013 Aug 12. [Medline].

  • Brooks M. Depression accelerates cognitive decline in type 2 diabetes. Medscape Medical News. October 17, 2013. [Full Text].

  • Sullivan MD, Katon WJ, Lovato LC, Miller ME, Murray AM, Horowitz KR, et al. Association of Depression With Accelerated Cognitive Decline Among Patients With Type 2 Diabetes in the ACCORD-MIND Trial. JAMA Psychiatry. 2013 Oct 1. 70(10):1041-7. [Medline].

  • reverses diabetes type 2 ominous octet (☑ pancreas) | reverses diabetes type 2 namehow to reverses diabetes type 2 for Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020. MMWR. 2020 Apr 8. [Full Text].

  • King J. Inflammatory markers may explain COVID-19, diabetes dynamic. MDedge. 2020 Apr 15. [Full Text].

  • Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020 Mar 31. e3319. [Medline]. [Full Text].

  • Ahlqvist E, Storm P, Karajamaki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018 Mar 1. [Medline].

  • Davenport L. Diabetes Consists of Five Types, Not Two, Say Researchers. Medscape Medical News. 2018 Mar 1. [Full Text].

  • Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004 Jan 10. 363(9403):157-63. [Medline].

  • Wei GS, Coady SA, Goff DC Jr, Brancati FL, Levy D, Selvin E, et al. Blood pressure and the risk of developing diabetes in african americans and whites: ARIC, CARDIA, and the framingham heart study. Diabetes Care. 2011 Apr. 34(4):873-9. [Medline]. [Full Text].

  • Dabelea D, Pettitt DJ, Hanson RL, Imperatore G, Bennett PH, Knowler WC. Birth weight, type 2 diabetes, and insulin resistance in Pima Indian children and young adults. Diabetes Care. 1999 Jun. 22(6):944-50. [Medline].

  • Yarbrough DE, Barrett-Connor E, Kritz-Silverstein D, Wingard DL. Birth weight, adult weight, and girth as predictors of the metabolic syndrome in postmenopausal women: the Rancho Bernardo Study. Diabetes Care. 1998 Oct. 21(10):1652-8. [Medline].

  • Li Y, Qi Q, Workalemahu T, Hu FB, Qi L. Birth Weight, Genetic Susceptibility, and Adulthood Risk of Type 2 Diabetes. Diabetes Care. 2012 Aug 24. [Medline].

  • Slining MM, Kuzawa CW, Mayer-Davis EJ, Adair LS. Evaluating the indirect effect of infant weight velocity the 1 last update 02 Jun 2020 on insulin resistance in young adulthood: a birth cohort study from the Philippines. Am J Epidemiol. 2011 Mar 15. 173(6):640-8. [Medline]. [Full Text].Slining MM, Kuzawa CW, Mayer-Davis EJ, Adair LS. Evaluating the indirect effect of infant weight velocity on insulin resistance in young adulthood: a birth cohort study from the Philippines. Am J Epidemiol. 2011 Mar 15. 173(6):640-8. [Medline]. [Full Text].

  • Wang J, Luben R, Khaw KT, Bingham S, Wareham NJ, Forouhi NG. Dietary energy density predicts the risk of incident type 2 diabetes: the European Prospective Investigation of Cancer (EPIC)-Norfolk Study. Diabetes Care. 2008 Nov. 31(11):2120-5. [Medline]. [Full Text].

  • Hectors TL, Vanparys C, van der Ven K, Martens GA, Jorens PG, Van Gaal LF, et al. Environmental pollutants and type 2 diabetes: a review of mechanisms that can disrupt beta cell function. Diabetologia. 2011 Jun. 54(6):1273-90. [Medline].

  • de Miguel-Yanes JM, Shrader P, Pencina MJ, Fox CS, Manning AK, Grant RW, et al. Genetic risk reclassification for type 2 diabetes by age below or above 50 years using 40 type 2 diabetes risk single nucleotide polymorphisms. Diabetes Care. 2011 Jan. 34(1):121-5. [Medline]. [Full Text].

  • Winckler W, Weedon MN, Graham RR, McCarroll SA, Purcell S, Almgren P, et al. Evaluation of common variants in the six known maturity-onset the 1 last update 02 Jun 2020 diabetes of the young (MODY) genes for association with type 2 diabetes. Diabetes. 2007 Mar. 56(3):685-93. [Medline]. Winckler W, Weedon MN, Graham RR, McCarroll SA, Purcell S, Almgren P, et al. Evaluation of common variants in the six known maturity-onset diabetes of the young (MODY) genes for association with type 2 diabetes. Diabetes. 2007 Mar. 56(3):685-93. [Medline].

  • Molven A, Ringdal M, Nordbo AM, Raeder H, Stoy J, Lipkind GM, et al. Mutations in the insulin gene can cause MODY and autoantibody-negative type 1 diabetes. Diabetes. 2008 Apr. 57(4):1131-5. [Medline].

  • Neve B, Fernandez-Zapico ME, Ashkenazi-Katalan V, Dina C, Hamid YH, Joly E, et al. Role of transcription factor KLF11 and its diabetes-associated gene variants in pancreatic beta cell function. Proc Natl Acad Sci U S A. 2005 Mar 29. 102(13):4807-12. [Medline]. [Full Text].

  • Raeder H, Johansson S, Holm PI, Haldorsen IS, Mas E, Sbarra V, et al. Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction. Nat Genet. 2006 Jan. 38(1):54-62. [Medline].

  • Plengvidhya N, Kooptiwut S, Songtawee N, Doi A, Furuta H, Nishi M, et al. PAX4 mutations in Thais with maturity onset diabetes of the young. J Clin Endocrinol Metab. 2007 Jul. 92(7):2821-6. [Medline].

  • Borowiec M, Liew CW, Thompson R, Boonyasrisawat W, Hu J, Mlynarski WM, et al. Mutations at the BLK locus linked to maturity onset diabetes of the young and beta-cell dysfunction. Proc Natl Acad Sci U S A. 2009 Aug 25. 106(34):14460-5. [Medline]. [Full Text].

  • reverses diabetes type 2 oatmeal (🔴 guidelines 2020) | reverses diabetes type 2 hba1chow to reverses diabetes type 2 for Edghill EL, Bingham C, Ellard S, Hattersley AT. Mutations in hepatocyte nuclear factor-1beta and their related phenotypes. J Med Genet. 2006 Jan. 43(1):84-90. [Medline]. [Full Text].

  • van den Ouweland JM, Lemkes HH, Ruitenbeek W, Sandkuijl LA, de Vijlder MF, Struyvenberg PA, et al. Mutation in mitochondrial tRNA(Leu)(UUR) gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness. Nat Genet. 1992 Aug. 1(5):368-71. [Medline].

  • Castellino AM. Genetically Lowered Birth Weight May Cause Type 2 Diabetes. Medscape Medical News. July 4, 2016. [Full Text].

  • reverses diabetes type 2 killer (🔥 insulin pump) | reverses diabetes type 2 ricehow to reverses diabetes type 2 for Wang T, Huang T, Li Y, Zheng Y, Manson JE, Hu FB, et al. Low birthweight and risk of type 2 diabetes: a Mendelian randomisation study. Diabetologia. 2016 Jun 23. [Medline].

  • Pan A, Lucas M, Sun Q, van Dam RM, Franco OH, Manson JE, et al. Bidirectional association between depression and type 2 for 1 last update 02 Jun 2020 diabetes mellitus in women. Arch Intern Med. 2010 Nov 22. 170(21):1884-91. [Medline]. [Full Text].Pan A, Lucas M, Sun Q, van Dam RM, Franco OH, Manson JE, et al. Bidirectional association between depression and type 2 diabetes mellitus in women. Arch Intern Med. 2010 Nov 22. 170(21):1884-91. [Medline]. [Full Text].

  • Nouwen A, Winkley K, Twisk J, Lloyd CE, Peyrot M, Ismail K, et al. Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis. Diabetologia. 2010 Dec. 53(12):2480-6. [Medline]. [Full Text].

  • Siuta MA, Robertson SD, Kocalis H, Saunders C, Gresch PJ, Khatri V, et al. Dysregulation of the norepinephrine transporter sustains cortical hypodopaminergia and schizophrenia-like behaviors in neuronal rictor null mice. PLoS Biol. 2010 Jun 8. 8(6):e1000393. [Medline]. [Full Text].

  • Feig DS, Shah BR, Lipscombe LL, Wu CF, Ray JG, Lowe J, et al. Preeclampsia as a risk factor for diabetes: a population-based cohort study. PLoS Med. 2013 Apr. 10(4):e1001425. [Medline]. [Full Text].

  • Andes LJ, Cheng YJ, Rolka DB, Gregg EW, Imperatore G. Prevalence of Prediabetes Among Adolescents and Young Adults in the United States, 2005-2016. JAMA Pediatr. 2019 Dec 2. e194498. [Medline]. [Full Text].

  • Dunleavy BP. Prevalence of prediabetes high among U.S. teens, young adults. 2019 Dec 2. Available at https://www.upi.com/Health_News/2019/12/02/Prevalence-of-prediabetes-high-among-US-teens-young-adults/8591575297926/.

  • Hackethal V. 2 in 5 American Adults Will Develop Diabetes. Medscape for 1 last update 02 Jun 2020 Medical News. Available at http://www.medscape.com/viewarticle/829833. Accessed: August 13, 2014.Hackethal V. 2 in 5 American Adults Will Develop Diabetes. Medscape Medical News. Available at http://www.medscape.com/viewarticle/829833. Accessed: August 13, 2014.

  • Gregg EW, Zhuo X, Albright AL, et al. Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985—2011: a modelling study. The Lancet Diabetes & Endocrinology. Available at http://www.thelancet.com/journals/landia/article/PIIS2213-8587(14)70161-5/fulltext. Accessed: August 13, 2014.

  • Ludwig J, Sanbonmatsu L, Gennetian the 1 last update 02 Jun 2020 L, Adam E, Duncan GJ, Katz LF, et al. Neighborhoods, obesity, and diabetes--a randomized social experiment. N Engl J Med. 2011 Oct 20. 365(16):1509-19. [Medline]. Ludwig J, Sanbonmatsu L, Gennetian L, Adam E, Duncan GJ, Katz LF, et al. Neighborhoods, obesity, and diabetes--a randomized social experiment. N Engl J Med. 2011 Oct 20. 365(16):1509-19. [Medline].

  • One adult in ten will have diabetes by 2030. International Diabetes Federation. November 14, 2011. Available at http://www.idf.org/media-events/press-releases/2011/diabetes-atlas-5th-edition.

  • Selvin E, Steffes MW, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL. Racial differences in glycemic markers: a cross-sectional analysis of community-based data. Ann Intern Med. 2011 Mar 1. 154(5):303-9. [Medline]. [Full Text].

  • Albers JW, Herman WH, Pop-Busui R, Feldman EL, Martin CL, Cleary PA, et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care. 2010 May. 33(5):1090-6. [Medline]. [Full Text].

  • White NH, Sun W, Cleary PA, Tamborlane WV, Danis RP, Hainsworth DP, et al. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes. 2010 May. 59(5):1244-53. [Medline]. [Full Text].

  • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12. 352(9131):837-53. [Medline].

  • Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet. 2012 Jun 16. 379(9833):2243-51. [Medline].

  • Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct 9. 359(15):1577-89. [Medline].

  • Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med. 2008 Jun 12. 358(24):2630-3. [Medline].

  • Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol. 2009 Jan 20. 53(3):298-304. [Medline].

  • reverses diabetes type 2 use insulin (🔥 ncbi) | reverses diabetes type 2 pumps systemhow to reverses diabetes type 2 for Duckworth for 1 last update 02 Jun 2020 W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009 Jan 8. 360(2):129-39. [Medline]. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009 Jan 8. 360(2):129-39. [Medline].

  • Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbek A, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet. 2011 Jul 9. 378(9786):156-67. [Medline]. [Full Text].

  • Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008 Feb 7. 358(6):580-91. [Medline].

  • Kerr D, Partridge H, Knott J, Thomas PW. HbA1c 3 months after diagnosis predicts premature mortality in patients with new onset type 2 diabetes. Diabet Med. 2011 Dec. 28(12):1520-4. [Medline].

  • Gruss C, Gutierrez C, Burhans WC, DePamphilis ML, Koller T, Sogo JM. Nucleosome assembly in mammalian cell extracts before and after DNA replication. EMBO J. 1990 Sep. 9(9):2911-22. [Medline]. [Full Text].

  • Zheng F, Yan L, Yang Z, Zhong B, Xie W. HbA1c, diabetes and cognitive decline: the English Longitudinal Study of Ageing. Diabetologia. 2018 Jan 25. [Medline]. [Full Text].

  • Melville NA. HbA1c Levels in Diabetes Linked to Cognitive Decline. Medscape Medical News. 2018 Jan 30. [Full Text].

  • Cano JF, Baena-Diez JM, Franch J, Vila J, Tello S, Sala J, et al. Long-term cardiovascular risk in type 2 diabetic compared with nondiabetic first acute myocardial infarction patients: a population-based cohort study in southern Europe. Diabetes Care. 2010 Sep. 33(9):2004-9. [Medline]. [Full Text].

  • Yamasaki Y, Nakajima K, Kusuoka H, Izumi T, Kashiwagi A, Kawamori R, et al. Prognostic value of gated myocardial perfusion imaging for asymptomatic patients with type 2 diabetes: the J-ACCESS 2 investigation. Diabetes Care. 2010 Nov. 33(11):2320-6. [Medline]. [Full Text].

  • Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA. 2009 Apr 15. 301(15):1547-55. [Medline]. [Full Text].

  • Murthy VL, Naya M, Foster CR, Gaber M, Hainer J, Klein J, et al. Association Between Coronary Vascular Dysfunction and Cardiac Mortality in Patients with and without Diabetes Mellitus. Circulation. 2012 Aug 23. [Medline].

  • U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Available at http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed: January 5, 2012.

  • National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes Statistics, 2011. National Diabetes Information Clearinghouse. Available at http://diabetes.niddk.nih.gov/dm/pubs/statistics/. Accessed: January 5, 2012.

  • Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med. 2011 Mar 14. 171(5):404-10. [Medline].

  • Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011 Mar 3. 364(9):829-41. [Medline].

  • Lind M, Olsson M, Rosengren A, Svensson AM, Bounias I, Gudbjornsdottir S. The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes. Diabetologia. 2012 Aug 16. [Medline].

  • Shah AS, Khoury PR, Dolan LM, Ippisch HM, Urbina EM, Daniels SR, et al. The effects of obesity and type 2 diabetes mellitus on cardiac structure and function in adolescents and young adults. Diabetologia. 2011 Apr. 54(4):722-30. [Medline].

  • Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. Diabetes the 1 last update 02 Jun 2020 Care. 2010 Jul. 33(7):1674-85. [Medline]. [Full Text].Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010 Jul. 33(7):1674-85. [Medline]. [Full Text].

  • Tseng CH. Diabetes for 1 last update 02 Jun 2020 and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia. 2011 Aug. 54(8):2009-15. [Medline]. Tseng CH. Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia. 2011 Aug. 54(8):2009-15. [Medline].

  • Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ. 2012 Jul 3. [Medline].

  • Yin M, Zhou J, Gorak EJ, Quddus F. Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis. Oncologist. 2013 Nov 20. [Medline]. [Full Text].

  • Nelson R. Metformin boosts survival in diabetic cancer patients. Medscape Medical News. November 25, 2013. [Full Text].

  • reverses diabetes type 2 is characterized as (🔥 fasting) | reverses diabetes type 2 doctor near mehow to reverses diabetes type 2 for Lopez-de-Andres A, Perez-Farinos N, de Miguel-Diez J, et al. Type 2 diabetes and postoperative pneumonia: An observational, population-based study using the Spanish Hospital Discharge Database, 2001-2015. PLoS One. 2019. 14 (2):e0211230. [Medline]. [Full Text].

  • Bode B, Garrett V, Messler J, et al. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States. J Diabetes Sci Technol. 2020. [Full Text].

  • Tucker ME. Pay Attention to In-Hospital Glucose to Save Lives in COVID-19. Medscape Medical News. 2020 Apr 20. [Full Text].

  • Murphy HR, Steel SA, Roland JM, Morris D, Ball V, Campbell PJ, et al. Obstetric and perinatal outcomes in pregnancies complicated by Type 1 and Type 2 diabetes: influences of glycaemic control, obesity and social disadvantage. Diabet Med. 2011 Sep. 28(9):1060-7. [Medline]. [Full Text].

  • Sperl-Hillen J, Beaton S, Fernandes O, Von Worley A, Vazquez-Benitez G, Parker E, et al. Comparative effectiveness of patient education methods for type 2 diabetes: a randomized controlled trial. Arch Intern Med. 2011 Dec 12. 171(22):2001-10. [Medline].

  • Khunti K, Gray LJ, Skinner T, Carey ME, Realf K, Dallosso H, et al. Effectiveness of a diabetes education and self management programme (DESMOND) for people with newly diagnosed type 2 diabetes mellitus: three year follow-up of a cluster randomised controlled trial in primary care. BMJ. 2012 Apr 26. 344:e2333. [Medline]. [Full Text].

  • Duke SA, Colagiuri S, Colagiuri R. Individual patient education for people with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2009 Jan 21. CD005268. [Medline].

  • Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care. 1992 Jul. 15(7):815-9. [Medline].

  • Nainggolan L. Dawn Phenomenon Affects Half of Type 2 Diabetes Patients. Medscape Medical News. Nov 7 2013. [Full Text].

  • Monnier L, Colette C, Dejager S, et the 1 last update 02 Jun 2020 al. Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern?. Diabetes Care. 2013 Oct 29. [Medline]. Monnier L, Colette C, Dejager S, et al. Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern?. Diabetes Care. 2013 Oct 29. [Medline].

  • Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA. 2007 Aug 22. 298(8):902-16. [Medline].

  • reverses diabetes type 2 herpes (🔥 jogging) | reverses diabetes type 2 hba1chow to reverses diabetes type 2 for Frank RN. Diabetic retinopathy. N Engl J Med. 2004 Jan 1. 350(1):48-58. [Medline].

  • Ding J, Strachan MW, Fowkes FG, Wong TY, Macgillivray TJ, Patton N, et al. Association of retinal arteriolar dilatation with lower verbal memory: the Edinburgh Type 2 Diabetes Study. Diabetologia. 2011 Jul. 54(7):1653-62. [Medline].

  • reverses diabetes type 2 doctor near me (🔥 by race) | reverses diabetes type 2 unspecifiedhow to reverses diabetes type 2 for Hujoel PP, Stott-Miller M. Retinal and gingival hemorrhaging and chronic hyperglycemia. Diabetes Care. 2011 Jan. 34(1):181-3. [Medline]. [Full Text].

  • reverses diabetes type 2 young age complications (👍 patho) | reverses diabetes type 2 breakfast menuhow to reverses diabetes type 2 for [Guideline] American Association of Clinical Endocrinologists Statement on the Use of A1C for the Diagnosis of Diabetes. Available at https://www.aace.com/files/AACEpositionA1cfeb2010.pdf. Accessed: May 14 2012.

  • World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. World Health Organization, Geneva, 2006. Available at http://whqlibdoc.who.int/publications/2006/9241594934_eng.pdf.

  • Brambilla P, La Valle E, Falbo R, Limonta G, Signorini S, Cappellini F, et al. Normal fasting plasma glucose and risk of type 2 diabetes. Diabetes Care. 2011 Jun. 34(6):1372-4. [Medline]. [Full Text].

  • [Guideline] Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, et al. Executive summary: guidelines and recommendations for for 1 last update 02 Jun 2020 laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2011 Jun. 57(6):793-8. [Medline]. [Guideline] Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, et al. Executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2011 Jun. 57(6):793-8. [Medline].

  • International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009 Jul. 32(7):1327-34. [Medline]. [Full Text].

  • Huang ES, Liu JY, Moffet HH, John PM, Karter AJ. Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. Diabetes Care. 2011 Jun. 34(6):1329-36. [Medline]. [Full Text].

  • Wang W, Lee ET, Howard BV, Fabsitz RR, Devereux RB, Welty TK. Fasting plasma glucose and hemoglobin A1c in identifying and predicting diabetes: the strong heart study. Diabetes Care. 2011 Feb. 34(2):363-8. [Medline]. [Full Text].

  • Brooks M. Hemoglobin A1c misses many cases of diabetes. Medscape. 2019 Mar 28. [Full Text].

  • Nowicka P, Santoro N, Liu H, Lartaud D, Shaw MM, Goldberg R, et al. Utility of hemoglobin A(1c) for diagnosing prediabetes and diabetes in obese children and adolescents. Diabetes Care. 2011 Jun. 34(6):1306-11. [Medline]. [Full Text].

  • Vijayakumar P, Nelson RG, Hanson RL, Knowler WC, Sinha M. HbA1c and the Prediction of Type 2 Diabetes in Children and Adults. Diabetes Care. 2017 Jan. 40 (1):16-21. [Medline]. [Full Text].

  • Davenport L. HbA1c Predicts Diabetes Risk in Children and Adolescents. Medscape Medical News. 2017 Jan 4. [Full Text].

  • Lu ZX, Walker KZ, O''Most''s Effect in Diabetes Linked to Gut Microbiota Changes. Medscape Medical News. 2018 Nov 29. [Full Text].

  • reverses diabetes type 2 nursing (☑ lifestyle changes) | reverses diabetes type 2 nature reviewhow to reverses diabetes type 2 for Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999 Jun 2. 281(21):2005-12. [Medline].

  • UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group. Diabetes Care. 1998 Jan. 21(1):87-92. [Medline].

  • Qaseem A, Barry MJ, Humphrey LL, Forciea MA, Clinical Guidelines Committee of the American College of Physicians. Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians. Ann Intern Med. 2017 Jan 3. [Medline]. [Full Text].

  • Tucker ME. ACP Updates Guidelines for Type 2 Diabetes Care. Medscape Medical News. 2017 Jan 3. [Full Text].

  • Vashisht R, Jung K, Schuler A, et al. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative. JAMA Net Open. 2018 Aug 24. 1(4):[Full Text].

  • Tucker ME. Big Data Confirm Type 2 Diabetes Treatment Approach. Medscape Medical News. 2018 Aug 31. [Full Text].

  • reverses diabetes type 2 with intermittent fasting (⭐️ explanation) | reverses diabetes type 2 videohow to reverses diabetes type 2 for Kooy A, de Jager J, Lehert P, Bets D, Wulffele MG, Donker AJ, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009 Mar 23. 169(6):616-25. [Medline].

  • Pradhan AD, Everett BM, Cook NR, Rifai N, Ridker PM. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. JAMA. 2009 Sep 16. 302(11):1186-94. [Medline].

  • Andersson C, Olesen JB, Hansen PR, Weeke P, Norgaard ML, Jorgensen CH, et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia. 2010 Dec. 53(12):2546-53. [Medline].

  • Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC Jr, Goto S, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med. 2010 Nov 22. 170(21):1892-9. [Medline].

  • Gross JL, Kramer CK, Leitão CB, Hawkins N, Viana LV, Schaan BD, et al. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med. 2011 May 17. 154(10):672-9. [Medline].

  • reverses diabetes type 2 is characterized as (☑ use insulin) | reverses diabetes type 2 use insulinhow to reverses diabetes type 2 for Zeller M, Danchin N, Simon D, Vahanian A, Lorgis L, Cottin Y, et al. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab. 2010 Nov. 95(11):4993-5002. [Medline].

  • Bellomo Damato A, Stefanelli G, Laviola L, Giorgino R, Giorgino F. Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia. Diabet Med. 2011 May. 28(5):560-6. [Medline].

  • Retnakaran R, Qi Y, Harris SB, Hanley AJ, Zinman B. Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance. Diabetes Care. 2011 Jul. 34(7):1601-4. [Medline]. [Full Text].

  • DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011 Mar 24. 364(12):1104-15. [Medline].

  • Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006 Sep 23. 368(9541):1096-105. [Medline].

  • Phung OJ, Sood NA, Sill BE, Coleman CI. Oral anti-diabetic drugs for the prevention of Type 2 diabetes. Diabet Med. 2011 Aug. 28(8):948-64. [Medline].

  • Charpentier G, Halimi S. Earlier triple therapy with pioglitazone in patients with type 2 diabetes. Diabetes Obes Metab. 2009 Sep. 11(9):844-54. [Medline].

  • Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005 Oct 8. 366(9493):1279-89. [Medline].

  • reverses diabetes type 2 occur (👍 with diet) | reverses diabetes type 2 joint painhow to reverses diabetes type 2 for Rennings AJ, Russel FG, Li Y, Deen PM, Masereeuw R, Tack CJ, et al. Preserved response to diuretics in rosiglitazone-treated subjects with insulin resistance: a randomized double-blind placebo-controlled crossover study. Clin Pharmacol Ther. 2011 Apr. 89(4):587-94. [Medline].

  • Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011 Apr. 34(4):916-22. [Medline]. [Full Text].

  • Ferrara A, Lewis JD, Quesenberry CP Jr, Peng T, Strom BL, Van Den Eeden SK, et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care. 2011 Apr. 34(4):923-9. [Medline]. [Full Text].

  • Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care. 2011 Jun. 34(6):1369-71. [Medline]. [Full Text].

  • Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type for 1 last update 02 Jun 2020 2 diabetes: a meta-analysis. CMAJ. 2009 Jan 6. 180(1):32-9. [Medline]. [Full Text].Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009 Jan 6. 180(1):32-9. [Medline]. [Full Text].

  • US Food and Drug Administration. FDA Drug Safety Communication: Updated Risk Evaluation and Mitigation Strategy (REMS) to Restrict Access to Rosiglitazone-containing Medicines including Avandia, Avandamet, and Avandaryl. Available at http://www.fda.gov/Drugs/DrugSafety/ucm255005.htm. Accessed: January 20, 2012.

  • Bunck MC, Diamant M, Corner A, Eliasson B, Malloy JL, Shaginian RM, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2009 May. 32(5):762-8. [Medline]. [Full Text].

  • Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011 Jan 18. 154(2):103-12. [Medline].

  • Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008 Oct 4. 372(9645):1240-50. [Medline].

  • Pencek R, Blickensderfer A, Li Y, Brunell SC, Chen S. Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations. Int J Clin Pract. 2012 Aug 24. [Medline].

  • Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011 May. 96(5):1301-10. [Medline].

  • Douglas D. Exenatide More Effective Than Insulin Detemir: Study. Available at http://www.medscape.com/viewarticle/777411. Accessed: January 15, 2013.

  • Davies M, Heller S, Sreenan S, Sapin H, Adetunji O, Tahbaz A, et al. Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas. Diabetes Care. 2012 Dec 28. [Medline].

  • Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28. 375 (4):311-22. [Medline]. [Full Text].

  • Tamborlane WV, Barrientos-Perez M, Fainberg U, et al. Liraglutide in Children and Adolescents with Type 2 Diabetes. N Engl J Med. 2019 Apr 28. [Medline].

  • US Food and Drug Administration. FDA approves Tanzeum to treat type 2 diabetes [press release]. April 15, 2014. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm393289.htm. Accessed: April 21, 2014.

  • Busko M. FDA approves weekly injectable diabetes drug: albiglutide. Medscape Medical News. April 15, 2014. [Full Text].

  • Douglas D. Albiglutide Long-Acting Option for Diabetes Control. Medscape Medical News. Available at http://www.medscape.com/viewarticle/821700. Accessed: March 17, 2014.

  • Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014. Feb 6. [Epub ahead of print].

  • Tucker M. FDA Approves Once-Weekly Dulaglutide for Type 2 for 1 last update 02 Jun 2020 Diabetes. Medscape Medical News. Available at http://www.medscape.com/viewarticle/831969. Accessed: September 26, 2014.Tucker M. FDA Approves Once-Weekly Dulaglutide for Type 2 Diabetes. Medscape Medical News. Available at http://www.medscape.com/viewarticle/831969. Accessed: September 26, 2014.

  • Wysham C, Blevins T, Arakaki R, Colon G, Garcia P, Atisso C, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014 Aug. 37(8):2159-67. [Medline].

  • reverses diabetes type 2 epidemiology (🔴 zhongwen) | reverses diabetes type 2 teenshow to reverses diabetes type 2 for Umpierrez G, Tofe Povedano S, Perez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014 Aug. 37(8):2168-76. [Medline].

  • Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014 Aug. 37(8):2149-58. [Medline]. [Full Text].

  • Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019 Jul 13. 394 (10193):121-30. [Medline].

  • Ahren B, Galstyan G, Gautier JF, et al. Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis. Diabetes Ther. 2016 Jun 18. [Medline].

  • Yabe D, Ambos A, Cariou B, et al. Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials. J Diabetes Complications. 2016 May 24. [Medline]. [Full Text].

  • Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015 Dec 3. 373 (23):2247-57. [Medline]. [Full Text].

  • Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care. 2012 Jun. 35(6):1225-31. [Medline]. [Full Text].

  • Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10. 375 (19):1834-44. [Medline]. [Full Text].

  • reverses diabetes type 2 explanation (👍 go away) | reverses diabetes type 2 is characterized byhow to reverses diabetes type 2 for Tucker ME. FDA Approves CVD Benefit for Once-Weekly Semaglutide. Medscape Medical News. 2020 Jan 17. [Full Text].

  • Ozempic (semaglutide SC) [package insert]. Plainsboro, NJ: Novo Nordisk. January 2020. Available at [Full Text].

  • Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes for 1 last update 02 Jun 2020 Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA. 2019 Apr 16. 321 (15):1466-80. [Medline]. [Full Text].Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA. 2019 Apr 16. 321 (15):1466-80. [Medline]. [Full Text].

  • Rodbard HW, Rosenstock J, Canani LH, et al. Oral Semaglutide versus Empagliflozin in Patients with Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care. 2019 Sep 17. [Medline].

  • reverses diabetes type 2 eating plan (🔴 symptoms in women) | reverses diabetes type 2 diet ukhow to reverses diabetes type 2 for Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019 Jul 6. 394 (10192):39-50. [Medline].

  • Rybelsus (semaglutide oral) [package insert]. Plainsboro, NJ: Novo Nordisk. January 2020. Available at [Full Text].

  • Aschner P, Katzeff HL, Guo H, Sunga S, Williams-Herman D, Kaufman KD, et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab. 2010 Mar. 12(3):252-61. [Medline].

  • Vilsboll T, Rosenstock J, Yki-Jarvinen H, Cefalu WT, Chen Y, Luo E, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2010 Feb. 12(2):167-77. [Medline].

  • Perez-Monteverde A, Seck T, Xu L, Lee MA, Sisk CM, Williams-Herman DE, et al. Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes. Int J Clin Pract. 2011 Sep. 65(9):930-8. [Medline].

  • Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med. 2011 Nov. 28(11):1352-61. [Medline].

  • Willemen MJ, Mantel-Teeuwisse AK, Straus SM, Meyboom RH, Egberts TC, Leufkens HG. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care. 2011 Feb. 34(2):369-74. [Medline]. [Full Text].

  • Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care. 2011 Nov. 34(11):2474-6. [Medline]. [Full Text].

  • Nainggolan L. FDA approves canagliflozin, a first-in-class diabetes drug. March 29, 2013. Medscape Medical News. Available at http://www.medscape.com/viewarticle/781709. Accessed: April 2, 2013.

  • US Food and Drug Administration. FDA approves Invokana to treat type 2 diabetes [press release]. March 29, 2013. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm. Accessed: April 2, 2013.

  • Tucker M. FDA Approves Dapagliflozin (Farxiga) for Type 2 Diabetes Treatment. Medscape Medical News. Available at http://www.medscape.com/viewarticle/818858. Accessed: January 13, 2014.

  • FDA News Release. FDA approves Farxiga to treat type 2 diabetes. U.S. Food and Drug Administration. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm380829.htm. Accessed: January 13, 2014.

  • Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes for 1 last update 02 Jun 2020 Endocrinol. 2013 Nov. 1(3):208-19. [Medline]. Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013 Nov. 1(3):208-19. [Medline].

  • Ridderstrale M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014 Jun 16. [Medline].

  • Stenlof K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, et al. Efficacy and safety of canagliflozin monotherapy for 1 last update 02 Jun 2020 in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013 Apr. 15(4):372-82. [Medline]. [Full Text].Stenlof K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013 Apr. 15(4):372-82. [Medline]. [Full Text].

  • Clar C, Gill JA, Court R, Waugh N. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open. 2012. 2(5):[Medline]. [Full Text].

  • reverses diabetes type 2 example (👍 untreated) | reverses diabetes type 2 optionshow to reverses diabetes type 2 for Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 Jun 13. 380 (24):2295-306. [Medline].

  • Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012 Mar 20. 156(6):405-15. [Medline].

  • Nauck MA, Del Prato S, Meier JJ, Duran-Garcia S, Rohwedder K, Elze M, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011 Sep. 34(9):2015-22. [Medline]. [Full Text].

  • Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011 Oct. 13(10):928-38. [Medline].

  • Rosenstock J, Vico M, Wei for 1 last update 02 Jun 2020 L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012 Jul. 35(7):1473-8. [Medline]. [Full Text].Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012 Jul. 35(7):1473-8. [Medline]. [Full Text].

  • Wiviott SD, Raz I, Bonaca MP, et for 1 last update 02 Jun 2020 al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24. 380 (4):347-57. [Medline]. [Full Text].Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24. 380 (4):347-57. [Medline]. [Full Text].

  • Tucker ME. FDA Approves Empagliflozin for Reducing CVD Death. Medscape Medical News. 2016 Dec 2. [Full Text].

  • Peters AL. '': Diabetes Drug With CV Benefits. Medscape. 2016 Dec 21. [Full Text].

  • Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26. 373 (22):2117-28. [Medline]. [Full Text].

  • Terra SG, Focht K, Davies M, et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017 May. 19 (5):721-8. [Medline].

  • Rosenstock J, Frias J, Pall D, et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2017 Aug 31. [Medline].

  • Dagogo-Jack S, Liu J, Eldor R, et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab. 2017 Sep 17. [Medline]. [Full Text].

  • de la Pena A, Riddle M, Morrow LA, Jiang HH, Linnebjerg H, Scott A, et al. Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects. Diabetes Care. 2011 Dec. 34(12):2496-501. [Medline]. [Full Text].

  • Agency for Healthcare Research and Quality. Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes. AHRQ: Agency for Healthcare Research and Quality. Available at http://www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?productid=108&pageaction=displayproduct.. Accessed: March 7, 2012.

  • Blair HA, Keating GM. Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus. Drugs. 2016 Mar. 76 (3):363-74. [Medline].

  • Toujeo. US Food and Drug Administration. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206538s006lbl.pdf. Accessed: 2018 Apr 25.

  • reverses diabetes type 2 health promotion (👍 zucchini) | reverses diabetes type 2 ketonehow to reverses diabetes type 2 for Davies MJ, Gross JL, Ono Y, Sasaki T, Bantwal G, Gall MA, et al. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial. Diabetes Obes Metab. 2014 Oct. 16 (10):922-30. [Medline]. [Full Text].

  • Zinman B, DeVries JH, Bode B, Russell-Jones D, Leiter LA, Moses A, et al. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. Lancet Diabetes Endocrinol. 2013 Oct. 1 (2):123-31. [Medline].

  • Zinman B, Fulcher G, Rao PV, Thomas N, Endahl LA, Johansen T, et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet. 2011 Mar 12. 377(9769):924-31. [Medline].

  • Afrezza (insulin inhaled) prescribing information [package insert]. Valencia CA, United States: MannKind Corporation. June 2014. Available at [Full Text].

  • Fiasp (insulin aspart) [package insert]. 800 Scudders Mill Road, Plainsboro, NJ 08536: Novo Nordisk Inc. September 2017. Available at [Full Text].

  • reverses diabetes type 2 australia (⭐️ uncontrolled icd 10) | reverses diabetes type 2 in childrenhow to reverses diabetes type 2 for Nainggolan L. FDA Approves New Fast-Acting Insulin, Fiasp, for Diabetes in Adults. Medscape Medical News. 2017 Sep 29. [Full Text].

  • US Food and Drug Administration. Early Communication About Safety of Lantus (Insulin Glargine). [Full Text].

  • Suissa S, Azoulay L, Dell''Connor CM, Ezrokhi M, Rutty D, Ma ZJ, et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care. 2010 Jul. 33(7):1503-8. [Medline]. [Full Text].

  • Bolen S, Wilson L, Vassy J, Feldman L, Yeh J, Marinopoulos S, et al. Undefined. 2007 Jul. [Medline].

  • Bennett WL, Wilson LM, Bolen S, Maruthur N, Singh S, Chatterjee R, et al. Undefined. 2011 Mar. [Medline].

  • reverses diabetes type 2 high blood sugar (☑ immune system) | reverses diabetes type 2 levelhow to reverses diabetes type 2 for Tucker ME. New AACE algorithm addresses all aspects of type 2 diabetes. Medscape Medical News. April 23, 2013. [Full Text].

  • [Guideline] Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. AACE Comprehensive Diabetes Management Algorithm 2013. Endocr Pract. 2013 Mar-Apr. 19(2):327-36. [Medline].

  • Boule NG, Robert C, Bell GJ, Johnson ST, Bell RC, Lewanczuk RZ, et al. Metformin and exercise in type 2 diabetes: examining treatment modality interactions. Diabetes Care. 2011 Jul. 34(7):1469-74. [Medline]. [Full Text].

  • Brooks M. Metformin Cuts Dementia Risk in Type 2 Diabetes. Medscape Medical News. Available at http://www.medscape.com/viewarticle/807886. Accessed: July 23, 2013.

  • Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009 Sep-Oct. 15(6):540-59. [Medline].

  • Qayyum R, Bolen S, Maruthur N, Feldman L, Wilson LM, Marinopoulos SS, et al. Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med. 2008 Oct 21. 149(8):549-59. [Medline].

  • Porcellati F, Lucidi P, Rossetti P, Candeloro P, Andreoli AM, Marzotti S, et al. Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine, and detemir in type 2 diabetes mellitus. Diabetes Care. 2011 Dec. 34(12):2521-3. [Medline]. [Full Text].

  • Baldwin D, Zander J, Munoz C, Raghu P, Delange-Hudec S, Lee H, et al. A Randomized Trial of Two Weight-Based Doses of Insulin Glargine and Glulisine in Hospitalized Subjects With Type 2 Diabetes and Renal Insufficiency. Diabetes Care. 2012 Jun 14. [Medline].

  • Grunberger G, Abelseth JM, Bailey TS, Bode BW, Handelsman Y, Hellman R. Consensus statement by the american association of clinical endocrinologists/american college of endocrinology insulin pump management task force. Endocr Pract. 2014 May 1. 20(5):463-89. [Medline].

  • Fritsche A, Larbig M, Owens D, Haring HU. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. Diabetes Obes Metab. 2010 Feb. 12(2):115-23. [Medline].

  • Siegelaar SE, Kerr L, Jacober SJ, Devries JH. A decrease in glucose variability does not reduce cardiovascular event rates in type 2 diabetic patients after acute for 1 last update 02 Jun 2020 myocardial infarction: a reanalysis of the HEART2D study. Diabetes Care. 2011 Apr. 34(4):855-7. [Medline]. [Full Text].Siegelaar SE, Kerr L, Jacober SJ, Devries JH. A decrease in glucose variability does not reduce cardiovascular event rates in type 2 diabetic patients after acute myocardial infarction: a reanalysis of the HEART2D study. Diabetes Care. 2011 Apr. 34(4):855-7. [Medline]. [Full Text].

  • Chen MJ, Jovanovic A, Taylor R. Utilizing the second-meal effect in type 2 diabetes: practical use of a soya-yogurt snack. Diabetes Care. 2010 Dec. 33(12):2552-4. [Medline]. [Full Text].

  • Qaseem A, Vijan S, Snow V, Cross JT, Weiss KB, Owens DK. Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians. Ann Intern Med. 2007 Sep 18. 147(6):417-22. [Medline].

  • Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, et al. Effect of intensive glucose lowering treatment on all for 1 last update 02 Jun 2020 cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011 Jul 26. 343:d4169. [Medline]. [Full Text].Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011 Jul 26. 343:d4169. [Medline]. [Full Text].

  • reverses diabetes type 2 eating (👍 e119) | reverses diabetes type 2 younghow to reverses diabetes type 2 for Tucker ME. Diabetes in the Elderly Addressed in Consensus Report. Medscape Medical News. October 25, 2012. Accessed November 13, 2012.

  • Sue Kirkman M, Briscoe VJ, Clark N, et al. Diabetes in Older Adults: A Consensus Report. J Am Geriatr Soc. 2012 Oct the 1 last update 02 Jun 2020 25. [Medline]. Sue Kirkman M, Briscoe VJ, Clark N, et al. Diabetes in Older Adults: A Consensus Report. J Am Geriatr Soc. 2012 Oct 25. [Medline].

  • Klonoff DC, Buckingham B, Christiansen JS, Montori VM, Tamborlane WV, Vigersky RA, et al. Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011 Oct. 96(10):2968-79. [Medline].

  • Ahmedani MY, Ul Haque MS, Basit A, Fawwad A, Alvi SF. Ramadan Prospective Diabetes Study: the role of drug dosage and timing alteration, active glucose monitoring and patient education. Diabet Med. 2012 Jan 11. [Medline].

  • Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011 Jul. 34(7):1481-6. [Medline]. [Full Text].

  • Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013 Jul 11. 369(2):145-54. [Medline]. [Full Text].

  • Lazo M, Solga SF, Horska A, Bonekamp S, Diehl AM, Brancati FL, et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 the 1 last update 02 Jun 2020 diabetes. Diabetes Care. 2010 Oct. 33(10):2156-63. [Medline]. [Full Text].Lazo M, Solga SF, Horska A, Bonekamp S, Diehl AM, Brancati FL, et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care. 2010 Oct. 33(10):2156-63. [Medline]. [Full Text].

  • Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2017 Dec 5. [Full Text].

  • Nainggolan L. Liquid Diet, Gradual Reintroduction of Food, Prompts for 1 last update 02 Jun 2020 Diabetes Remission. Medscape. 2017 Dec 5. [Full Text].Nainggolan L. Liquid Diet, Gradual Reintroduction of Food, Prompts Diabetes Remission. Medscape. 2017 Dec 5. [Full Text].

  • Esposito K, Maiorino MI, Ciotola M, Di Palo C, Scognamiglio P, Gicchino M, et al. Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a randomized trial. Ann Intern Med. 2009 Sep 1. 151(5):306-14. [Medline].

  • Larsen RN, Mann NJ, Maclean E, Shaw JE. The effect of high-protein, low-carbohydrate diets in the treatment of type 2 diabetes: a 12 month randomised controlled trial. Diabetologia. 2011 Apr. 54(4):731-40. [Medline].

  • Bassil M, Burgos S, Marliss EB, Morais JA, Chevalier S, Gougeon R. Hyperaminoacidaemia at postprandial levels does not modulate glucose metabolism in type 2 diabetes mellitus. Diabetologia. 2011 Jul. 54(7):1810-8. [Medline].

  • Mozaffarian D, Cao H, King IB, Lemaitre RN, Song X, Siscovick DS, et al. Trans-palmitoleic acid, metabolic risk factors, and new-onset diabetes in U.S. adults: a cohort study. Ann Intern Med. 2010 Dec 21. 153(12):790-9. [Medline]. [Full Text].Mozaffarian D, Cao H, King IB, Lemaitre RN, Song X, Siscovick DS, et al. Trans-palmitoleic acid, metabolic risk factors, and new-onset diabetes in U.S. adults: a cohort study. Ann Intern Med. 2010 Dec 21. 153(12):790-9. [Medline]. [Full Text].

  • Uribarri J, Cai W, Ramdas M, Goodman S, Pyzik R, Chen X, et al. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care. 2011 Jul. 34(7):1610-6. [Medline]. [Full Text].

  • Reeds DN, Patterson BW, Okunade A, Holloszy JO, Polonsky KS, Klein S. Ginseng and ginsenoside Re do not improve ß-cell function or insulin sensitivity in overweight and obese subjects with impaired glucose tolerance or diabetes. Diabetes Care. 2011 May. 34(5):1071-6. [Medline]. [Full Text].

  • Clerici C, Nardi E, Battezzati PM, Asciutti S, Castellani D, Corazzi N, et al. Novel soy germ pasta improves endothelial function, blood pressure, and oxidative stress in patients with type 2 diabetes. Diabetes Care. 2011 Sep. 34(9):1946-8. [Medline]. [Full Text].

  • n-3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia. N Engl J Med. 2012 Jun 11. [Medline].

  • Umpierre D, Ribeiro PA, Kramer CK, Leitao CB, Zucatti AT, Azevedo MJ, et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2011 May 4. 305(17):1790-9. [Medline].

  • Balducci S, Zanuso S, Nicolucci A, De Feo P, Cavallo S, Cardelli P, et al. Effect of an intensive exercise intervention strategy on modifiable cardiovascular risk factors in subjects with type 2 diabetes mellitus: a randomized controlled trial: the Italian Diabetes and Exercise Study (IDES). Arch Intern Med. 2010 Nov 8. 170(20):1794-803. [Medline].

  • Church TS, Blair SN, Cocreham S, Johannsen N, Johnson W, Kramer K, et al. Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2010 Nov 24. 304(20):2253-62. [Medline]. [Full Text].

  • Chudyk A, Petrella RJ. Effects of exercise on cardiovascular risk factors in type 2 diabetes: a meta-analysis. Diabetes Care. 2011 May. 34(5):1228-37. [Medline]. [Full Text].

  • Loimaala A, Groundstroem K, Rinne M, Nenonen A, Huhtala H, Parkkari J, et al. Effect of long-term endurance and strength training on metabolic control and arterial elasticity in patients with type 2 diabetes mellitus. Am J Cardiol. 2009 Apr 1. 103(7):972-7. [Medline].

  • Hegde SV, Adhikari P, Kotian S, Pinto VJ, D''Souza V. Effect of 3-month yoga on oxidative stress in type 2 diabetes with or without complications: a controlled clinical trial. Diabetes Care. 2011 Oct. 34(10):2208-10. [Medline]. [Full the 1 last update 02 Jun 2020 Text].Hegde SV, Adhikari P, Kotian S, Pinto VJ, D''Souza V. Effect of 3-month yoga on oxidative stress in type 2 diabetes with or without complications: a controlled clinical trial. Diabetes Care. 2011 Oct. 34(10):2208-10. [Medline]. [Full Text].

  • Dixon JB, Zimmet P, Alberti KG, Rubino F. Bariatric surgery: an IDF statement for obese Type 2 diabetes. Diabet Med. 2011 Jun. 28(6):628-42. [Medline]. [Full Text].

  • Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7. 346(6):393-403. [Medline]. [Full Text].

  • Davenport L. '' Guidelines on Role of Bariatric Surgery in Diabetes. Medscape Medical News. May 25, 2016. [Full Text].

  • Rubino F, Nathan DM, Eckel RH, et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care. 2016 Jun. 39 (6):861-77. [Medline]. [Full Text].

  • Kashyap SR, Bhatt DL, Wolski K, Watanabe RM, Abdul-Ghani M, Abood B, et al. Metabolic Effects of Bariatric Surgery in Patients With Moderate Obesity and Type 2 Diabetes: Analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care. 2013 Feb 25. [Medline].

  • Tucker ME. Bariatric Surgery: Many Can Come Off Insulin Long Term. Medscape. 2017 Nov 6. [Full Text].

  • Cigolle CT, Lee PG, Langa KM, Lee YY, Tian Z, Blaum CS. Geriatric conditions develop in middle-aged adults with diabetes. J Gen Intern Med. 2011 Mar. 26(3):272-9. [Medline]. [Full Text].

  • Schernhammer E, Hansen J, Rugbjerg K, Wermuth L, Ritz B. Diabetes and the risk of developing Parkinson''s disease: a systematic review and meta-analysis. Diabetes Care. 2011 Dec. 34(12):2614-23. [Medline]. [Full Text].

  • Chen HF, Chen P, Li CY. Risk of malignant neoplasm of the pancreas in relation to diabetes: a population-based study in Taiwan. Diabetes Care. 2011 May. 34(5):1177-9. [Medline]. [Full Text].

  • Kanaya AM, Adler N, Moffet HH, Liu for 1 last update 02 Jun 2020 J, Schillinger D, Adams A, et al. Heterogeneity of diabetes outcomes among asians and pacific islanders in the US: the diabetes study of northern california (DISTANCE). Diabetes Care. 2011 Apr. 34(4):930-7. [Medline]. [Full Text].Kanaya AM, Adler N, Moffet HH, Liu J, Schillinger D, Adams A, et al. Heterogeneity of diabetes outcomes among asians and pacific islanders in the US: the diabetes study of northern california (DISTANCE). Diabetes Care. 2011 Apr. 34(4):930-7. [Medline]. [Full Text].

  • Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998 Sep 12. 317(7160):703-13. [Medline]. [Full Text].

  • Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998 Jun 13. 351(9118):1755-62. [Medline].

  • [Guideline] de Boer IH, Bangalore S, Benetos A, et al. Diabetes and Hypertension: A Position Statement by the American Diabetes Association. Diabetes Care. 2017 Sep. 40 (9):1273-84. [Medline]. [Full Text].

  • [Guideline] Jenkins K. ADA Updates Recommendations for Managing Hypertension in Diabetes. Medscape. 4 Sep 2017. [Full Text].

  • Anderson RJ, Bahn GD, Moritz TE, Kaufman D, Abraira C, Duckworth W. Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care. 2011 Jan. 34(1):34-8. [Medline]. [Full Text].

  • reverses diabetes type 2 fruits (🔴 treatment guidelines) | reverses diabetes type 2 overweighthow to reverses diabetes type 2 for FDA Drug Safety Communication: FDA review of cardiovascular risks for diabetics taking hypertension drug olmesartan not conclusive; label updates required. US Food and Drug Administration. Available at http://www.fda.gov/Drugs/DrugSafety/ucm402323.htm. Accessed: June 29, 2014.

  • reverses diabetes type 2 normal range chart (🔴 pills) | reverses diabetes type 2 yogahow to reverses diabetes type 2 for O''Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018 Oct 4. [Medline]. [Full Text].

  • reverses diabetes type 2 vegan (🔴 recommendations) | reverses diabetes type 2 on insulinhow to reverses diabetes type 2 for [Guideline] Ivers NM, Jiang M, Alloo J, et al. Diabetes Canada 2018 clinical practice guidelines: Key messages for family physicians caring for patients living with type 2 diabetes. Can Fam Physician. 2019 Jan. 65 (1):14-24. [Medline]. [Full Text].

  • [Guideline] LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019 May 1. 104 (5):1520-74. [Medline]. [Full Text].

  • [Guideline] Tucker ME. New Endocrine Society Guidelines Address Diabetes in Older Adults. Medscape Medical News. 2019 Mar 23. [Full Text].

  • [Guideline] Busko M. ESC Diabetes and CVD Guideline: '' New Evidence. Medscape Medical for 1 last update 02 Jun 2020 News. 2019 Sep 2. [Full Text].[Guideline] Busko M. ESC Diabetes and CVD Guideline: '' New Evidence. Medscape Medical News. 2019 Sep 2. [Full Text].

  • [Guideline] Tucker ME. More Guidance on '' With Diabetes and COVID-19. Medscape Medical News. 2020 Apr 28. [Full Text].

  • [Guideline] Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020 Apr 23. [Medline]. [Full Text].

  • Tucker M. FDA Approves Inhaled Insulin Afrezza for Diabetes. Medscape Medical News. Available at http://www.medscape.com/viewarticle/827539. Accessed: July 5, 2014.

  • Tucker M. FDA OKs Xigduo XR, a New Dapagliflozin-Metformin Combo. Medscape Medical News. Available at http://www.medscape.com/viewarticle/834133. Accessed: November 10, 2014.

  • [Guideline] Tucker ME. USPSTF: screen everyone 45 and older for abnormal glucose. Medscape Medical News. Oct 6 2014. [Full Text].

  • [Guideline] USPSTF. Public comment on draft recommendation statement and draft evidence review: screening for abnormal glucose and type 2 diabetes mellitus. US Preventive Services Task Force. Available at http://www.uspreventiveservicestaskforce.org/Announcements/News/Item/public-comment-on-draft-recommendation-statement-and-draft-evidence-review-screening-for-abnormal-glucose-and-type-2-diabetes-mellitus. Accessed: Oct 14 2014.

  • Media Gallery for 1 last update 02 Jun 2020
    • Simplified scheme for the pathophysiology of type 2 diabetes mellitus.
    • Prevalence of type 2 diabetes mellitus in various racial and ethnic groups in the United States (2007-2009 data).
    • Prevalence of diabetes mellitus type 2 by age in the United States (2007 estimates).
    • Possible physical examination findings in patients with type 2 diabetes mellitus.
    • Diagnostic criteria (American Diabetes Association) for diabetes mellitus type 2.
    • Major findings from the primary glucose study in the United Kingdom Prospective Diabetes Study (UKPDS).
    • Results from metformin substudy in the United Kingdom Prospective Diabetes Study (UKPDS).
    • Findings from the blood pressure substudy in the United Kingdom Prospective Diabetes Study (UKPDS).
    • Laboratory monitoring guidelines for patients with type 2 diabetes mellitus.
    • American Diabetes Association guidelines for low-density lipoprotein cholesterol in diabetes mellitus type 2.
    • Treatment of type 2 diabetes mellitus.
    • Types of insulin. Premixed insulins can be assumed to have a combination of the onset, peak, and duration of the individual components.
    • Simplified scheme for using insulin in treating patients with type 2 diabetes mellitus.
    • Simplified scheme of idealized blood glucose values and multiple dose insulin therapy in type 2 diabetes mellitus.
    of 14
    Tables
      reverses diabetes type 2 obese (☑ your guide to getting started) | reverses diabetes type 2 vs 1how to reverses diabetes type 2 for
      Contributor Information and Disclosures
      Author

      Romesh Khardori, MD, PhD, FACP Professor of Endocrinology, Director of Training Program, Division of Endocrinology, Diabetes and Metabolism, Strelitz Diabetes and Endocrine Disorders Institute, Department of Internal Medicine, Eastern Virginia Medical School

      Romesh Khardori, MD, PhD, FACP is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Physicians, American Diabetes Association, Endocrine Society

      Disclosure: Nothing to disclose.

      Chief Editor

      reverses diabetes type 2 youth statistics (☑ nutrition) | reverses diabetes type 2 normal range charthow to reverses diabetes type 2 for George T Griffing, MD Professor Emeritus of Medicine, St Louis University School of Medicine

      George T Griffing, MD is a member of the following medical societies: American Association for the Advancement of Science, International Society for Clinical Densitometry, Southern Society for Clinical Investigation, American College of Medical Practice Executives, American Association for Physician Leadership, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical and Translational Research, Endocrine Society

      Disclosure: Nothing to disclose.

      Acknowledgements

      Howard A Bessen, MD Professor of Medicine, Department of Emergency Medicine, University of California, Los Angeles, David Geffen School of Medicine; Program Director, Harbor-UCLA Medical Center

      Howard A Bessen, MD is a member of the following medical societies: American College of Emergency Physicians

      Disclosure: Nothing to disclose.

      Barry E Brenner, MD, PhD, FACEP Professor of Emergency Medicine, Professor of Internal Medicine, Program Director, Emergency Medicine, Case Medical Center, University Hospitals, Case Western Reserve University School of Medicine

      Barry E Brenner, MD, PhD, FACEP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Chest Physicians, American College of Emergency Physicians, American College of Physicians, American Heart Association, American Thoracic Society, Arkansas Medical Society, New York Academy of Medicine, New York Academy ofSciences,and Society for Academic Emergency Medicine

      Disclosure: Nothing to disclose.

      William L Isley, MD Senior Associate Consultant, Associate Professor of Medicine, Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic for 1 last update 02 Jun 2020 of RochesterWilliam L Isley, MD Senior Associate Consultant, Associate Professor of Medicine, Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic of Rochester

      William L Isley, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Diabetes Association, American Federation for Medical Research, Endocrine Society, and Phi Beta Kappa

      Disclosure: Nothing to disclose.

      Kenneth Patrick L Ligaray, MD Fellow, Department of Endocrinology, Diabetes and Metabolism, St Louis University School of Medicine

      reverses diabetes type 2 mellitus is primarily a problem with (👍 treatment without medication) | reverses diabetes type 2 webmdhow to reverses diabetes type 2 for Kenneth Patrick Ligaray, MD is a member of the following medical societies: American Association of Clinical Endocrinologists and Endocrine Society

      Disclosure: Nothing to disclose.

      Anne L Peters, MD, CDE Director of Clinical Diabetes Programs, Professor, Department of Medicine, University of Southern California, Keck School of Medicine, Los Angeles, California, Los Angeles County/University of Southern California Medical Center

      Anne L Peters, MD, CDE is a member of the following medical societies: American College of Physicians and American Diabetes Association

      Disclosure: Amylin Honoraria Speaking and teaching; AstraZeneca Consulting fee Consulting; Lilly Consulting fee Consulting; Takeda Consulting fee Consulting; Bristol Myers Squibb Honoraria Speaking and teaching; NovoNordisk Consulting fee Consulting; Medtronic Minimed Consulting fee Consulting; Dexcom Honoraria Speaking and teaching; Roche Honoraria Speaking and teaching

      David S Schade, MD Chief, Division of Endocrinology and Metabolism, Professor, Department of Internal Medicine, University of New Mexico School of Medicine and Health Sciences Center

      reverses diabetes type 2 with weight loss (👍 josh axe) | reverses diabetes type 2 is characterized ashow to reverses diabetes type 2 for David S Schade, MD is a member of the following medical societies: American College of Physicians, American Diabetes Association, American Federation for Medical Research, Endocrine Society, New Mexico Medical Society, New York Academy of Sciences, and Society for Experimental Biology and Medicine

      Disclosure: Nothing to disclose.

      Don S Schalch, MD Professor Emeritus, Department of Internal Medicine, Division of Endocrinology, University of Wisconsin Hospitals and Clinics

      Don S Schalch, MD is a member of the following medical societies: American Diabetes Association, American Federation for Medical Research, Central Society for Clinical Research, and Endocrine Society

      reverses diabetes type 2 limits (👍 eating plan) | reverses diabetes type 2 food planhow to reverses diabetes type 2 for Disclosure: Nothing to disclose.

      reverses diabetes type 2 glucose levels chart (☑ range chart) | reverses diabetes type 2 remissionhow to reverses diabetes type 2 for Erik D Schraga, MD Staff Physician, Department of Emergency Medicine, Mills-Peninsula Emergency Medical Associates

      reverses diabetes type 2 kidshealth (👍 lecture) | reverses diabetes type 2 teenshow to reverses diabetes type 2 for Disclosure: Nothing to the 1 last update 02 Jun 2020 disclose. Disclosure: Nothing to disclose.

      Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

      Disclosure: Medscape Salary Employment

      Scott R Votey, MD Director of Emergency Medicine Residency, Ronald Reagan UCLA Medical Center; Professor of Medicine/Emergency Medicine, University of California, Los Angeles, David Geffen School of Medicine

      Scott R Votey, MD is a member of the following medical societies: Society for Academic the 1 last update 02 Jun 2020 Emergency MedicineScott R Votey, MD is a member of the following medical societies: Society for Academic Emergency Medicine

      Disclosure: Nothing to disclose.

      Close
      What would you like to print?
      What would you like to print?

      Find Us On

      Group 2 34A8E98B-62ED-4216-98D6-E986304F4C2E

      About

      About Medscape Privacy Policy Editorial Policy Cookies Terms of Use Advertising Policy Help Center

      Membership

      Become a Member Email Newsletters Manage My Account

      reverses diabetes type 2 questions and answers (🔥 natural cures treatments) | reverses diabetes type 2 your guide to getting startedhow to reverses diabetes type 2 for Apps

      Medscape CME & Education

      the 1 last update 02 Jun 2020 WebMDWebMD Network

      WebMD MedicineNet eMedicineHealth RxList WebMD Corporate

      Editions

      English Deutsch Español Français Português
      All material on this website is protected by copyright, Copyright © 1994-2020 by WebMD LLC. This website also contains material copyrighted by 3rd parties.
      encoded search term (Type 2 Diabetes Mellitus) and Type 2 Diabetes Mellitus
      reverses diabetes type 2 patho (👍 born) | reverses diabetes type 2 naturally with diethow to reverses diabetes type 2 for What to Read Next on Medscape
      Related Conditions and Diseases
      Medscape Consult
      News & Perspective
      Tools
      Slideshow
      Top News From EASD 2018: Slideshow
      Most Popular Articles
      According to Endocrinologists
      1. ESC Says Continue Hypertension Meds Despite COVID-19 Concern
      2. COVID-19 and Diabetes: Patterns Emerge
      3. 2020 ADA Standards: A 'New Concept' in Treating T2D
      4. Pay Attention to In-Hospital Glucose to Save Lives in COVID-19
      5. Patients on Steroids With COVID-19 Might Need Rescue Steroids
      View More

      Recommended

      Need a Curbside Consult? Share cases and questions with Physicians on Medscape consult. Share a Case